Towson University again denied new degree due to similarity to one at Morgan State
BOSTON — Forty years ago, Heisman Trophy winner Doug Flutie rolled to his right and threw a pass that has become one of college football’s most iconic moments. With Boston College trailing defending champion Miami, Flutie threw the Hail Mary and found receiver Gerard Phalen, who made the grab while falling into the end zone behind a pair of defenders for a game-winning 48-yard TD. Flutie and many of his 1984 teammates were honored on the field during BC’s 41-21 victory over North Carolina before the second quarter on Saturday afternoon, the anniversary of the Eagles’ Miracle in Miami. “There’s no way its been 40 years,” Flutie told The Associated Press on the sideline a few minutes before he walked out with some of his former teammates to be recognized after a video of The Play was shown on the scoreboards. A statue commemorating Doug Flutie's famed "Hail Mary" pass during a game against Miami on Nov. 23, 1994, sits outside Alumni Stadium at Boston College. Famous football plays often attain a legendary status with religious names like the "Immaculate Reception," the "Hail Mary" pass and the Holy Roller fumble. It’s a moment and highlight that’s not only played throughout decades of BC students and fans, but around the college football world. “What is really so humbling is that the kids 40 years later are wearing 22 jerseys, still,” Flutie said of his old number. “That amazes me.” That game was played on national TV the Friday after Thanksgiving. The ironic thing is it was originally scheduled for earlier in the season before CBS paid Rutgers to move its game against Miami, thus setting up the BC-Miami post-holiday matchup. Boston College quarterback Doug Flutie rejoices in his brother Darren's arms after B.C. defeats Miami with a last second touchdown pass on Nov. 23, 1984, in Miami. “It shows you how random some things are, that the game was moved,” Flutie said. “The game got moved to the Friday after Thanksgiving, which was the most watched game of the year. We both end up being nationally ranked and up there. All those things lent to how big the game itself was, and made the pass and the catch that much more relevant and remembered because so many people were watching.” There’s a statue of Flutie winding up to make The Pass outside the north gates at Alumni Stadium. Fans and visitors can often be seen taking photos there. “In casual conversation, it comes up every day,” Flutie said, when asked how many times people bring it up. “It brings a smile to my face every time we talk about it.” A week after the game-ending Flutie pass, the Eagles beat Holy Cross and before he flew off to New York to accept the Heisman. They went on to win the 49th Cotton Bowl on New Year’s Day. Boston College quarterback Doug Flutie evades Miami defensive tackle Kevin Fagan during the first quarter of a game on Nov. 23, 1984, in Miami, Fla. “Forty years seem almost like incomprehensible,” said Phalen, also standing on the sideline a few minutes after the game started. “I always say to Doug: ‘Thank God for social media. It’s kept it alive for us.”’ Earlier this week, current BC coach Bill O’Brien, 55, was asked if he remembered where he was 40 years ago. “We were eating Thanksgiving leftovers in my family room,” he said. “My mom was saying a Rosary in the kitchen because she didn’t like Miami and wanted BC to win. My dad, my brother and I were watching the game. “It was unbelievable,” he said. “Everybody remembers where they were for the Hail Mary, Flutie pass.” Mike Tyson, left, slaps Jake Paul during a weigh-in ahead of their heavyweight bout, Thursday, Nov. 14, 2024, in Irving, Texas. (AP Photo/Julio Cortez) In this image taken with a slow shutter speed, Spain's tennis player Rafael Nadal serves during a training session at the Martin Carpena Sports Hall, in Malaga, southern Spain, on Friday, Nov. 15, 2024. (AP Photo/Manu Fernandez) A fan takes a picture of the moon prior to a qualifying soccer match for the FIFA World Cup 2026 between Uruguay and Colombia in Montevideo, Uruguay, Friday, Nov. 15, 2024. (AP Photo/Santiago Mazzarovich) Rasmus Højgaard of Denmark reacts after missing a shot on the 18th hole in the final round of World Tour Golf Championship in Dubai, United Arab Emirates, Sunday, Nov. 17, 2024. (AP Photo/Altaf Qadri) Taylor Fritz of the United States reacts during the final match of the ATP World Tour Finals against Italy's Jannik Sinner at the Inalpi Arena, in Turin, Italy, Sunday, Nov. 17, 2024. (AP Photo/Antonio Calanni) Dallas Cowboys wide receiver Jalen Tolbert (1) fails to pull in a pass against Atlanta Falcons cornerback Dee Alford (20) during the second half of an NFL football game, Sunday, Nov. 3, 2024, in Atlanta. (AP Photo/ Brynn Anderson) Green Bay Packers quarterback Jordan Love, top right, scores a touchdown during the second half of an NFL football game against the Chicago Bears in Chicago, Sunday, Nov. 17, 2024. (AP Photo/Nam Y. Huh) India's Tilak Varma jumps in the air as he celebrates after scoring a century during the third T20 International cricket match between South Africa and India, at Centurion Park in Centurion, South Africa, Wednesday, Nov. 13, 2024. (AP Photo/Themba Hadebe) Columbus Blue Jackets defenseman Zach Werenski warms up before facing the Seattle Kraken in an NHL hockey game Tuesday, Nov. 12, 2024, in Seattle. (AP Photo/Lindsey Wasson) Kansas State players run onto the field before an NCAA college football game against Arizona State Saturday, Nov. 16, 2024, in Manhattan, Kan. (AP Photo/Charlie Riedel) A fan rapped in an Uruguay flag arrives to the stands for a qualifying soccer match against Colombia for the FIFA World Cup 2026 in Montevideo, Uruguay, Friday, Nov. 15, 2024. (AP Photo/Matilde Campodonico) People practice folding a giant United States flag before an NFL football game between the Buffalo Bills and the Kansas City Chiefs, Sunday, Nov. 17, 2024, in Orchard Park, N.Y. (AP Photo/Julia Demaree Nikhinson) Brazil's Marquinhos attempts to stop the sprinklers that were turned on during a FIFA World Cup 2026 qualifying soccer match against Venezuela at Monumental stadium in Maturin, Venezuela, Thursday, Nov. 14, 2024. (AP Photo/Ariana Cubillos) Dallas Stars center Mavrik Bourque, right, attempts to score while Minnesota Wild right wing Ryan Hartman (38) and Wild goaltender Filip Gustavsson (32) keep the puck out of the net during the second period of an NHL hockey game, Saturday, Nov. 16, 2024, in St. Paul, Minn. (AP Photo/Ellen Schmidt) Mike Tyson, left, fights Jake Paul during their heavyweight boxing match, Friday, Nov. 15, 2024, in Arlington, Texas. (AP Photo/Julio Cortez) Italy goalkeeper Guglielmo Vicario misses the third goal during the Nations League soccer match between Italy and France, at the San Siro stadium in Milan, Italy, Sunday, Nov. 17, 2024. (AP Photo/Luca Bruno) Cincinnati Bengals tight end Mike Gesicki (88) celebrates after scoring a touchdown against the Las Vegas Raiders during the second half of an NFL football game in Cincinnati, Sunday, Nov. 3, 2024. (AP Photo/Carolyn Kaster) President-elect Donald Trump attends UFC 309 at Madison Square Garden, Saturday, Nov. 16, 2024, in New York. (AP Photo/Evan Vucci) Slovakia's Rebecca Sramkova hits a return against Danielle Collins, of the United States, during a tennis match at the Billie Jean King Cup Finals at the Martin Carpena Sports Hall, Thursday, Nov. 14, 2024, in Malaga, southern Spain. (AP Photo/Manu Fernandez) St. John's guard RJ Luis Jr. (12) falls after driving to the basket during the second half of an NCAA college basketball game against New Mexico, Sunday, Nov. 17, 2024, in New York. (AP Photo/Pamela Smith) England's Anthony Gordon celebrates after scoring his side's second goal during the UEFA Nations League soccer match between England and the Republic of Ireland at Wembley stadium in London, Sunday, Nov. 17, 2024. (AP Photo/Kin Cheung) Las Vegas Raiders wide receiver DJ Turner, right, tackles Miami Dolphins wide receiver Malik Washington, left, on a punt return during the second half of an NFL football game, Sunday, Nov. 17, 2024, in Miami Gardens, Fla. (AP Photo/Lynne Sladky) UConn's Paige Bueckers (5) battles North Carolina's Laila Hull, right, for a loose ball during the second half of an NCAA college basketball game in Greensboro, N.C., Friday, Nov. 15, 2024. (AP Photo/Ben McKeown) Georgia's Georges Mikautadze celebrates after scoring his side's first goal during the UEFA Nations League, group B1 soccer match between Georgia and Ukraine at the AdjaraBet Arena in Batumi, Georgia, Saturday, Nov. 16, 2024. (AP Photo/Tamuna Kulumbegashvili) Fans argue in stands during the UEFA Nations League soccer match between France and Israel at the Stade de France stadium in Saint-Denis, outside Paris, Thursday Nov. 14, 2024. (AP Photo/Thibault Camus) Katie Taylor, left, lands a right to Amanda Serrano during their undisputed super lightweight title bout, Friday, Nov. 15, 2024, in Arlington, Texas. (AP Photo/Julio Cortez) Get local news delivered to your inbox!Cazzu Reappears: Is She Shaking Up Ángela Aguilar and Christian Nodal? The Argentine Artist Proves She’s Stronger Than Ever Is She Striking Where It Hurts Pepe Aguilar’s Daughter Most? After stepping away from social media due to the pain caused by Christian Nodal and Ángela Aguilar, Cazzu has finally made a strong comeback. The Argentine artist returned to Instagram, sharing a series of photos where she dances sensually, flaunting her figure, and delivering a statement that seems aimed at the Mexican stars. Cazzu made it clear that her world revolves around her and her daughter, Inti, using music as her therapy for healing. Several details in the series of photos caught attention: were they indirect messages to Ángela and Nodal? Cazzu Reappears, Doing the Unexpected Cazzu Reappears: Is She Shaking Up Ángela Aguilar and Christian Nodal? – IG: People en Español and Cazzu In one of the videos shared by Cazzu, she is seen moving to the rhythm of a bolero—a “coincidence,” as Ángela Aguilar recently released a bolero album. Adding to the speculation, another photo shows the Argentine showcasing what Christian Nodal has lost: her toned and sensual figure. One image in particular sparked rumors that she might be recording heartbreak songs about her ex, as it shows her with lyrics from a potential track. However, it could simply be a book she was reading while in the recording studio, though its theme seems to resonate with her past with Nodal. Cazzu’s Mysterious Message: Aimed at Christian Nodal and Ángela Aguilar? IG: Cazzu One photo caption read, “But what can the two of us do alone?” seemingly referencing her and her daughter, Inti. Even more striking was what followed: “Alone, it’s true, but with a hatred...” Could Cazzu be channeling her anger toward the Mexican singers and their betrayal? It appears she’s preparing new music, and her fans are cheering her on: “Queen,” “You’re a mother,” “The boss is stepping up,” “They’ll never meet another woman like you,” her followers wrote. “Such happiness, you’re slowly coming back,” “Goddess,” “Queen,” “Stronger than ever, we’re eager to hear you,” “Shining as always,” her fans commented. HERE IS THE SERIES OF PHOTOS AND VIDEOS SHE SHARED. Click on the image to listen to the podcast PHOTO: MundoNOW if(typeof custom_paginate == "function")custom_paginate()PRESS RELEASE PALO ALTO, Calif., Nov. 19, 2024 /PRNewswire/ -- As artificial intelligence (AI) continues to revolutionize industries, the cybersecurity field faces a dual-edged sword of opportunities and threats. StrongDM's latest report, " The State of AI in Cybersecurity ," highlights the growing concerns and readiness of cybersecurity professionals to tackle AI-driven challenges. Based on a survey of 600 cybersecurity professionals, the report sheds light on pressing issues around AI regulation, perceived threats, defense confidence, and the future of the cybersecurity workforce. Key Findings from the Survey: A Call for Regulation Amid Rapid AI Growth: The report reveals that 76% of surveyed professionals support "heavy regulation" of AI to mitigate potential risks. However, 15% worry that excessive oversight could stifle innovation. This underscores a need for balanced regulations that ensure security while fostering technological advancement. Growing Concern Over AI-Powered Attacks: AI's potential to enable new attack vectors is top of mind for cybersecurity professionals, with 87% citing concern over AI-driven threats. Malware and data breaches emerged as the leading AI-powered concerns, with 33% and 30% of respondents, respectively, indicating their apprehension over these types of attacks. Confidence Levels Are Low, but Hope Persists: The report highlights a stark contrast in preparedness, as only 33% of respondents expressed being "very confident" in their current defenses against AI threats. Meanwhile, 46% felt "somewhat confident," and 17% admitted their organizations were not ready for AI-driven attacks. These findings emphasize an urgent call for stronger strategies and investments to bolster AI-specific defenses. Companies Playing Catch-Up: StrongDM's research found that 65% of respondents admitted their organizations are not fully prepared for AI-driven threats. While 32% of companies are actively investing in AI defenses, 48% say there's still much to be done to close the gap. AI's Mixed Impact on the Cybersecurity Workforce: Despite the concerns surrounding AI, two-thirds of cybersecurity professionals maintain an optimistic outlook on the technology's impact on their jobs. 40% believe AI will enhance job roles without replacing them, and 25% foresee the creation of new job opportunities. Nonetheless, 30% expressed fears of job replacement, showcasing the nuanced views professionals hold on AI's future role in the workforce. Complete Study Results: https://www.strongdm.com/blog/state-of-ai-in-cybersecurity-report Methodology The report is based on a survey conducted in October 2024, targeting 600 US-based cybersecurity professionals. The survey was completed online via Pollfish, and responses were random, voluntary, and completely anonymous. About StrongDM StrongDM is at the forefront of cybersecurity, specializing in Zero Trust Privileged Access Management (PAM). Our innovative solutions focus on continuous, policy-based controls that leverage actions and context to enhance enterprise security. StrongDM's technology scrutinizes each interaction in real time, preventing breaches before they occur and ensuring secure, frustration-free access across all platforms. Supported by leading investors, including GV, Sequoia Capital, True Ventures, and Anchor Capital, StrongDM operates across North America, Europe, and Asia-Pacific, dedicated to setting new standards in cybersecurity and providing top-tier protection for today's digital enterprises. For more information, visit the StrongDM website .
Coleen Rooney delivered a touching message to her sons back home before she embarked on the recent I'm A Celebrity jungle trial. The viewing public decided that she would face the latest Bushtucker trial, and they also selected Radio 1's Dean McCullough, who has already had his fair share of trials in the camp with mixed outcomes. However, Coleen provided much-needed moral support after her husband Wayne rallied his social media followers to vote for her to face the next challenge, stating his belief that Coleen was eager to make her family proud. As they set off to tackle the task named Absolute Carnage, Coleen reached out with an affectionate message for her boys: "I'm excited for my boys back home to see me do something. Hopefully I'm gonna do well, I'm gonna try my best." During the trial, one celebrity would be confined to the back of the ute to collect stars that were secured with various locks requiring different tools to release them. The other stars' role was to search the garage for these tools and pass them over to their companion at the back of the ute. Dean took on the task of hunting for tools, leaving Coleen in the back of the ute where she had to tolerate cockroaches, crickets, giant mealworms and rats crawling all over her. Meanwhile, Dean was confronted with a challenge that had previously defeated him... fish guts, reports . Ant and Dec commended Coleen on her performance, telling her: "You were very calm, very quiet, you just got on with it." To which Coleen responded: "Yeah, that is my way of coping, silence, the silent treatment. " Earlier in the episode, Coleen shared more personal stories. She recounted to her campmates the time she met President-elect Donald Trump while her husband Wayne was managing D.C. United in Washington. She recalled: "When we lived in America, we were invited to the White House for , and we went in to meet Donald Trump. "And we walked in and we got to get the official photograph taken in front of the Christmas tree. So Donald Trump said to his son, 'see? Told ya, all the soccer players get the good looking girls'. And I told my mum, I was like 'dirty b******'." Wayne made an appearance on I'm A Celebrity Unpacked on Saturday (November 23) to show his support for his wife. The current Plymouth manager also hinted at having a new poem ready for her upon her return after Coleen revealed to viewers the former Manchester United striker's fondness for poetry.he celebrated a spectacular and historic victory by winning the after a thrilling final against the The match, held at the energetic Dignity Health Sports Park in Carson, California, saw the Galaxy secure a dramatic 2-1 victory. The atmosphere was electric as fans filled the stadium, eager to witness another step in the team's journey to the championship, as it was marked by determination and skill, culminating in this unforgettable match. opened the scoring with a brilliant strike, showcasing his agility and precision but the Red Bulls fought back with a goal from , leveling the score and intensifying the game's excitement. How the cup was won It was who ultimately sealed the victory for the Galaxy with a crucial goal, sending the crowd into a frenzy. This win marked the Galaxy's sixth MLS Cup title, reaffirming their legacy as one of the league's most successful franchises. The victory was especially significant as it ended a decade-long drought since their last championship in 2014. The team's resilience and unity throughout the season were evident in their performance, and this championship stands as a testament to their hard work and dedication. As the final whistle blew, the stadium erupted in cheers, and the players celebrated with their fans, basking in the glory of their achievement. The 2024 MLS Cup win is not just a title for the Galaxy as the ten long years of waiting were not expected and now that pain and disappointment is over.From Maui to the Caribbean, Thanksgiving tournaments a beloved part of college basketball
2025 Makeup Trends You're About to See Everywhere
2 AI Stocks to Buy in December and Hold for 20 Years
By BILL BARROW, Associated Press PLAINS, Ga. (AP) — Newly married and sworn as a Naval officer, Jimmy Carter left his tiny hometown in 1946 hoping to climb the ranks and see the world. Less than a decade later, the death of his father and namesake, a merchant farmer and local politician who went by “Mr. Earl,” prompted the submariner and his wife, Rosalynn, to return to the rural life of Plains, Georgia, they thought they’d escaped. The lieutenant never would be an admiral. Instead, he became commander in chief. Years after his presidency ended in humbling defeat, he would add a Nobel Peace Prize, awarded not for his White House accomplishments but “for his decades of untiring effort to find peaceful solutions to international conflicts, to advance democracy and human rights, and to promote economic and social development.” The life of James Earl Carter Jr., the 39th and longest-lived U.S. president, ended Sunday at the age of 100 where it began: Plains, the town of 600 that fueled his political rise, welcomed him after his fall and sustained him during 40 years of service that redefined what it means to be a former president. With the stubborn confidence of an engineer and an optimism rooted in his Baptist faith, Carter described his motivations in politics and beyond in the same way: an almost missionary zeal to solve problems and improve lives. Carter was raised amid racism, abject poverty and hard rural living — realities that shaped both his deliberate politics and emphasis on human rights. “He always felt a responsibility to help people,” said Jill Stuckey, a longtime friend of Carter’s in Plains. “And when he couldn’t make change wherever he was, he decided he had to go higher.” Carter’s path, a mix of happenstance and calculation , pitted moral imperatives against political pragmatism; and it defied typical labels of American politics, especially caricatures of one-term presidents as failures. “We shouldn’t judge presidents by how popular they are in their day. That’s a very narrow way of assessing them,” Carter biographer Jonathan Alter told the Associated Press. “We should judge them by how they changed the country and the world for the better. On that score, Jimmy Carter is not in the first rank of American presidents, but he stands up quite well.” Later in life, Carter conceded that many Americans, even those too young to remember his tenure, judged him ineffective for failing to contain inflation or interest rates, end the energy crisis or quickly bring home American hostages in Iran. He gained admirers instead for his work at The Carter Center — advocating globally for public health, human rights and democracy since 1982 — and the decades he and Rosalynn wore hardhats and swung hammers with Habitat for Humanity. Yet the common view that he was better after the Oval Office than in it annoyed Carter, and his allies relished him living long enough to see historians reassess his presidency. “He doesn’t quite fit in today’s terms” of a left-right, red-blue scoreboard, said U.S. Transportation Secretary Pete Buttigieg, who visited the former president multiple times during his own White House bid. At various points in his political career, Carter labeled himself “progressive” or “conservative” — sometimes both at once. His most ambitious health care bill failed — perhaps one of his biggest legislative disappointments — because it didn’t go far enough to suit liberals. Republicans, especially after his 1980 defeat, cast him as a left-wing cartoon. It would be easiest to classify Carter as a centrist, Buttigieg said, “but there’s also something radical about the depth of his commitment to looking after those who are left out of society and out of the economy.” Indeed, Carter’s legacy is stitched with complexities, contradictions and evolutions — personal and political. The self-styled peacemaker was a war-trained Naval Academy graduate who promised Democratic challenger Ted Kennedy that he’d “kick his ass.” But he campaigned with a call to treat everyone with “respect and compassion and with love.” Carter vowed to restore America’s virtue after the shame of Vietnam and Watergate, and his technocratic, good-government approach didn’t suit Republicans who tagged government itself as the problem. It also sometimes put Carter at odds with fellow Democrats. The result still was a notable legislative record, with wins on the environment, education, and mental health care. He dramatically expanded federally protected lands, began deregulating air travel, railroads and trucking, and he put human rights at the center of U.S. foreign policy. As a fiscal hawk, Carter added a relative pittance to the national debt, unlike successors from both parties. Carter nonetheless struggled to make his achievements resonate with the electorate he charmed in 1976. Quoting Bob Dylan and grinning enthusiastically, he had promised voters he would “never tell a lie.” Once in Washington, though, he led like a joyless engineer, insisting his ideas would become reality and he’d be rewarded politically if only he could convince enough people with facts and logic. This served him well at Camp David, where he brokered peace between Israel’s Menachem Begin and Epypt’s Anwar Sadat, an experience that later sparked the idea of The Carter Center in Atlanta. Carter’s tenacity helped the center grow to a global force that monitored elections across five continents, enabled his freelance diplomacy and sent public health experts across the developing world. The center’s wins were personal for Carter, who hoped to outlive the last Guinea worm parasite, and nearly did. As president, though, the approach fell short when he urged consumers beleaguered by energy costs to turn down their thermostats. Or when he tried to be the nation’s cheerleader, beseeching Americans to overcome a collective “crisis of confidence.” Republican Ronald Reagan exploited Carter’s lecturing tone with a belittling quip in their lone 1980 debate. “There you go again,” the former Hollywood actor said in response to a wonky answer from the sitting president. “The Great Communicator” outpaced Carter in all but six states. Carter later suggested he “tried to do too much, too soon” and mused that he was incompatible with Washington culture: media figures, lobbyists and Georgetown social elites who looked down on the Georgians and their inner circle as “country come to town.” Carter carefully navigated divides on race and class on his way to the Oval Office. Born Oct. 1, 1924 , Carter was raised in the mostly Black community of Archery, just outside Plains, by a progressive mother and white supremacist father. Their home had no running water or electricity but the future president still grew up with the relative advantages of a locally prominent, land-owning family in a system of Jim Crow segregation. He wrote of President Franklin Roosevelt’s towering presence and his family’s Democratic Party roots, but his father soured on FDR, and Jimmy Carter never campaigned or governed as a New Deal liberal. He offered himself as a small-town peanut farmer with an understated style, carrying his own luggage, bunking with supporters during his first presidential campaign and always using his nickname. And he began his political career in a whites-only Democratic Party. As private citizens, he and Rosalynn supported integration as early as the 1950s and believed it inevitable. Carter refused to join the White Citizens Council in Plains and spoke out in his Baptist church against denying Black people access to worship services. “This is not my house; this is not your house,” he said in a churchwide meeting, reminding fellow parishioners their sanctuary belonged to God. Yet as the appointed chairman of Sumter County schools he never pushed to desegregate, thinking it impractical after the Supreme Court’s 1954 Brown v. Board decision. And while presidential candidate Carter would hail the 1965 Voting Rights Act, signed by fellow Democrat Lyndon Johnson when Carter was a state senator, there is no record of Carter publicly supporting it at the time. Carter overcame a ballot-stuffing opponent to win his legislative seat, then lost the 1966 governor’s race to an arch-segregationist. He won four years later by avoiding explicit mentions of race and campaigning to the right of his rival, who he mocked as “Cufflinks Carl” — the insult of an ascendant politician who never saw himself as part the establishment. Carter’s rural and small-town coalition in 1970 would match any victorious Republican electoral map in 2024. Once elected, though, Carter shocked his white conservative supporters — and landed on the cover of Time magazine — by declaring that “the time for racial discrimination is over.” Before making the jump to Washington, Carter befriended the family of slain civil rights leader Martin Luther King Jr., whom he’d never sought out as he eyed the governor’s office. Carter lamented his foot-dragging on school integration as a “mistake.” But he also met, conspicuously, with Alabama’s segregationist Gov. George Wallace to accept his primary rival’s endorsement ahead of the 1976 Democratic convention. “He very shrewdly took advantage of his own Southerness,” said Amber Roessner, a University of Tennessee professor and expert on Carter’s campaigns. A coalition of Black voters and white moderate Democrats ultimately made Carter the last Democratic presidential nominee to sweep the Deep South. Then, just as he did in Georgia, he used his power in office to appoint more non-whites than all his predecessors had, combined. He once acknowledged “the secret shame” of white Americans who didn’t fight segregation. But he also told Alter that doing more would have sacrificed his political viability – and thus everything he accomplished in office and after. King’s daughter, Bernice King, described Carter as wisely “strategic” in winning higher offices to enact change. “He was a leader of conscience,” she said in an interview. Rosalynn Carter, who died on Nov. 19 at the age of 96, was identified by both husband and wife as the “more political” of the pair; she sat in on Cabinet meetings and urged him to postpone certain priorities, like pressing the Senate to relinquish control of the Panama Canal. “Let that go until the second term,” she would sometimes say. The president, recalled her former aide Kathy Cade, retorted that he was “going to do what’s right” even if “it might cut short the time I have.” Rosalynn held firm, Cade said: “She’d remind him you have to win to govern.” Carter also was the first president to appoint multiple women as Cabinet officers. Yet by his own telling, his career sprouted from chauvinism in the Carters’ early marriage: He did not consult Rosalynn when deciding to move back to Plains in 1953 or before launching his state Senate bid a decade later. Many years later, he called it “inconceivable” that he didn’t confer with the woman he described as his “full partner,” at home, in government and at The Carter Center. “We developed a partnership when we were working in the farm supply business, and it continued when Jimmy got involved in politics,” Rosalynn Carter told AP in 2021. So deep was their trust that when Carter remained tethered to the White House in 1980 as 52 Americans were held hostage in Tehran, it was Rosalynn who campaigned on her husband’s behalf. “I just loved it,” she said, despite the bitterness of defeat. Fair or not, the label of a disastrous presidency had leading Democrats keep their distance, at least publicly, for many years, but Carter managed to remain relevant, writing books and weighing in on societal challenges. He lamented widening wealth gaps and the influence of money in politics. He voted for democratic socialist Bernie Sanders over Hillary Clinton in 2016, and later declared that America had devolved from fully functioning democracy to “oligarchy.” Related Articles Yet looking ahead to 2020, with Sanders running again, Carter warned Democrats not to “move to a very liberal program,” lest they help re-elect President Donald Trump. Carter scolded the Republican for his serial lies and threats to democracy, and chided the U.S. establishment for misunderstanding Trump’s populist appeal. He delighted in yearly convocations with Emory University freshmen, often asking them to guess how much he’d raised in his two general election campaigns. “Zero,” he’d gesture with a smile, explaining the public financing system candidates now avoid so they can raise billions. Carter still remained quite practical in partnering with wealthy corporations and foundations to advance Carter Center programs. Carter recognized that economic woes and the Iran crisis doomed his presidency, but offered no apologies for appointing Paul Volcker as the Federal Reserve chairman whose interest rate hikes would not curb inflation until Reagan’s presidency. He was proud of getting all the hostages home without starting a shooting war, even though Tehran would not free them until Reagan’s Inauguration Day. “Carter didn’t look at it” as a failure, Alter emphasized. “He said, ‘They came home safely.’ And that’s what he wanted.” Well into their 90s, the Carters greeted visitors at Plains’ Maranatha Baptist Church, where he taught Sunday School and where he will have his last funeral before being buried on family property alongside Rosalynn . Carter, who made the congregation’s collection plates in his woodworking shop, still garnered headlines there, calling for women’s rights within religious institutions, many of which, he said, “subjugate” women in church and society. Carter was not one to dwell on regrets. “I am at peace with the accomplishments, regret the unrealized goals and utilize my former political position to enhance everything we do,” he wrote around his 90th birthday. The politician who had supposedly hated Washington politics also enjoyed hosting Democratic presidential contenders as public pilgrimages to Plains became advantageous again. Carter sat with Buttigieg for the final time March 1, 2020, hours before the Indiana mayor ended his campaign and endorsed eventual winner Joe Biden. “He asked me how I thought the campaign was going,” Buttigieg said, recalling that Carter flashed his signature grin and nodded along as the young candidate, born a year after Carter left office, “put the best face” on the walloping he endured the day before in South Carolina. Never breaking his smile, the 95-year-old host fired back, “I think you ought to drop out.” “So matter of fact,” Buttigieg said with a laugh. “It was somehow encouraging.” Carter had lived enough, won plenty and lost enough to take the long view. “He talked a lot about coming from nowhere,” Buttigieg said, not just to attain the presidency but to leverage “all of the instruments you have in life” and “make the world more peaceful.” In his farewell address as president, Carter said as much to the country that had embraced and rejected him. “The struggle for human rights overrides all differences of color, nation or language,” he declared. “Those who hunger for freedom, who thirst for human dignity and who suffer for the sake of justice — they are the patriots of this cause.” Carter pledged to remain engaged with and for them as he returned “home to the South where I was born and raised,” home to Plains, where that young lieutenant had indeed become “a fellow citizen of the world.” —- Bill Barrow, based in Atlanta, has covered national politics including multiple presidential campaigns for the AP since 2012.
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenOverhauls of 'heritage brands' raise the question: How important are our products to our identities?Calzada TD to Alexander sends Incarnate Word to FCS quarterfinal with win over Villanova
Dollar Tree ( NASDAQ:DLTR – Get Free Report ) had its price target upped by research analysts at Truist Financial from $79.00 to $83.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 15.49% from the company’s previous close. Several other research firms also recently issued reports on DLTR. Melius Research initiated coverage on shares of Dollar Tree in a research note on Monday, September 23rd. They set a “hold” rating and a $70.00 price target for the company. Piper Sandler reaffirmed a “neutral” rating and set a $72.00 target price (up from $67.00) on shares of Dollar Tree in a report on Thursday. StockNews.com cut Dollar Tree from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Evercore ISI cut their price objective on Dollar Tree from $94.00 to $92.00 and set an “in-line” rating on the stock in a research note on Tuesday. Finally, UBS Group decreased their target price on shares of Dollar Tree from $155.00 to $105.00 and set a “buy” rating for the company in a research report on Thursday, September 5th. Seventeen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $85.58. Read Our Latest Stock Analysis on Dollar Tree Dollar Tree Trading Down 1.0 % Dollar Tree ( NASDAQ:DLTR – Get Free Report ) last posted its earnings results on Wednesday, December 4th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.07 by $0.05. The firm had revenue of $7.57 billion during the quarter, compared to the consensus estimate of $7.45 billion. Dollar Tree had a positive return on equity of 15.77% and a negative net margin of 3.44%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the company earned $0.97 earnings per share. As a group, sell-side analysts expect that Dollar Tree will post 5.35 EPS for the current fiscal year. Institutional Inflows and Outflows Several institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers increased its position in shares of Dollar Tree by 203.5% during the first quarter. Cetera Investment Advisers now owns 12,596 shares of the company’s stock worth $1,677,000 after acquiring an additional 8,446 shares in the last quarter. Cetera Advisors LLC increased its holdings in Dollar Tree by 119.7% during the 1st quarter. Cetera Advisors LLC now owns 3,234 shares of the company’s stock worth $431,000 after purchasing an additional 1,762 shares in the last quarter. Mather Group LLC. raised its stake in shares of Dollar Tree by 198.9% in the second quarter. Mather Group LLC. now owns 281 shares of the company’s stock worth $30,000 after purchasing an additional 187 shares during the last quarter. Park Avenue Securities LLC lifted its holdings in shares of Dollar Tree by 82.3% in the second quarter. Park Avenue Securities LLC now owns 15,011 shares of the company’s stock valued at $1,603,000 after purchasing an additional 6,779 shares in the last quarter. Finally, Czech National Bank boosted its position in shares of Dollar Tree by 8.4% during the second quarter. Czech National Bank now owns 39,489 shares of the company’s stock valued at $4,216,000 after buying an additional 3,071 shares during the last quarter. Institutional investors and hedge funds own 97.40% of the company’s stock. About Dollar Tree ( Get Free Report ) Dollar Tree, Inc operates retail discount stores. The company operates in two segments, Dollar Tree and Family Dollar. The Dollar Tree segment offers merchandise at the fixed price of $ 1.25. It provides consumable merchandise, which includes everyday consumables, such as household paper and chemicals, food, candy, health, personal care products, and frozen and refrigerated food; variety merchandise comprising toys, durable housewares, gifts, stationery, party goods, greeting cards, softlines, arts and crafts supplies, and other items; and seasonal goods that include Christmas, Easter, Halloween, and Valentine's Day merchandise. Featured Stories Five stocks we like better than Dollar Tree What is Forex and How Does it Work? Trinity Capital CEO on Leading Private Credit’s High-Yield Growth Russell 2000 Index, How Investors Use it For Profitable Trading Lululemon Surges On Q3 Report: Analysts Step in To Support Market The 3 Best Fintech Stocks to Buy Now 10 Safe Investments with High Returns Receive News & Ratings for Dollar Tree Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dollar Tree and related companies with MarketBeat.com's FREE daily email newsletter .
Lea Miller-Tooley hopped off a call to welcome the Baylor women’s basketball team to the Atlantis resort in the Bahamas, where 80-degree temperatures made it easy for the Bears to settle in on Paradise Island a week before Thanksgiving. About 5,000 miles west of the Caribbean nation, similar climes awaited Maui Invitational men's teams in Hawaii. They’ve often been greeted with leis, the traditional Hawaiian welcome of friendship. College basketball teams and fans look forward to this time of the year. The holiday week tournaments feature buzzworthy matchups and all-day TV coverage, sure, but there is a familiarity about them as they help ward off the November chill. For four decades, these sandy-beach getaways filled with basketball have become a beloved mainstay of the sport itself. “When you see (ESPN’s) ‘Feast Week’ of college basketball on TV, when you see the Battle 4 Atlantis on TV, you know college basketball is back,” said Miller-Tooley, the founder and organizer of the Battle 4 Atlantis men's and women's tournaments. “Because it’s a saturated time of the year with the NFL, college football and the NBA. But when you see these gorgeous events in these beautiful places, you realize, ‘Wow, hoops are back, let’s get excited.’” The Great Alaska Shootout was the trend-setting multiple-team event (MTE) nearly five decades ago. The brainchild of late Alaska-Anchorage coach Bob Rachal sought to raise his program’s profile by bringing in national-power programs, which could take advantage of NCAA rules allowing them to exceed the maximum allotment of regular-season games if they played the three-game tournament outside the contiguous 48 states. The first edition, named the Sea Wolf Classic, saw N.C. State beat Louisville 72-66 for the title on Nov. 26, 1978. The Maui Invitational followed in November 1984, borne from the buzz of NAIA program Chaminade’s shocking upset of top-ranked Virginia and 7-foot-4 star Ralph Sampson in Hawaii two years earlier. Events kept coming, with warm-weather locales getting in on the action. The Paradise Jam in the U.S. Virgin Islands. The Cancun Challenge in Mexico. The Cayman Islands Classic. The Jamaica Classic. The Myrtle Beach Invitational joining the Charleston Classic in South Carolina. Numerous tournaments in Florida. Some events have faded away like the Puerto Rico Tipoff and the Great Alaska Shootout, the latter in 2017 amid event competition and schools opting for warm-weather locales. Notre Dame takes on Chaminade during the first half of a 2017 game in Lahaina, Hawaii. Miller-Tooley’s push to build an MTE for Atlantis began as a December 2010 doubleheader with Georgia Tech beating Richmond and Virginia Tech beating Mississippi State in a prove-it moment for a tournament’s viability. It also required changing NCAA legislation to permit MTEs in the Bahamas. Approval came in March 2011; the first eight-team Atlantis men’s tournament followed in November. That tournament quickly earned marquee status with big-name fields, with Atlantis champions Villanova (2017) and Virginia (2018) later winning that season’s NCAA title. Games run in a ballroom-turned-arena at the resort, where players also check out massive swimming pools, water slides and inner-tube rapids surrounded by palm trees and the Atlantic Ocean. “It’s just the value of getting your passport stamped, that will never get old,” Miller-Tooley said. “Watching some of these kids, this may be their first and last time – and staff and families – that they ever travel outside the United States. ... You can see through these kids’ eyes that it’s really an unbelievable experience.” ACC Network analyst Luke Hancock knows that firsthand. His Louisville team finished second at Atlantis in 2012 and won that year’s later-vacated NCAA title, with Hancock as the Final Four's most outstanding player. “I remember (then-coach Rick Pitino) saying something to the effect of: ‘Some of you guys might never get this opportunity again. We’re staying in this unbelievable place, you’re doing it with people you love,’” Hancock said. “It was a business trip for us there at Thanksgiving, but he definitely had a tone of ‘We’ve got to enjoy this as well.’” Maui offers similar vibes, though 2024 could be a little different as Lahaina recovers from deadly 2023 wildfires that forced the event's relocation last year. North Carolina assistant coach Sean May played for the Tar Heels’ Maui winner in 2004 and was part of UNC’s staff for the 2016 champion, with both teams later winning the NCAA title. May said “you just feel the peacefulness” of the area — even while focusing on games — and savors memories of the team taking a boat out on the Pacific Ocean after title runs under now-retired Hall of Famer Roy Williams. “Teams like us, Dukes, UConns – you want to go to places that are very well-run,” May said. “Maui, Lea Miller with her group at the Battle 4 Atlantis, that’s what drives teams to come back because you know you’re going to get standard A-quality of not only the preparation but the tournament with the way it’s run. Everything is top-notch. And I think that brings guys back year after year.” That’s why Colorado coach Tad Boyle is so excited for the Buffaloes’ first Maui appearance since 2009. “We’ve been trying to get in the tournament since I got here,” said Boyle, now in his 15th season. And of course, that warm-weather setting sure doesn’t hurt. “If you talk about the Marquettes of the world, St. John’s, Providence – they don’t want that cold weather,” said NBA and college TV analyst Terrence Oglesby, who played for Clemson in the 2007 San Juan Invitational in Puerto Rico. “They’re going to have to deal with that all January and February. You might as well get a taste of what the sun feels like.” Michigan State head coach Tom Izzo argues a call during the first half of a Nov. 16 game against Bowling Green in East Lansing, Michigan. Mi The men’s Baha Mar Championship in Nassau, Bahamas, got things rolling last week with No. 11 Tennessee routing No. 13 Baylor for the title. The week ahead could boast matchups befitting the Final Four, with teams having two weeks of action since any opening-night hiccups. “It’s a special kickoff to the college basketball season,” Oglesby said. “It’s just without the rust.” On the women’s side, Atlantis began its fourth eight-team women’s tournament Saturday with No. 16 North Carolina and No. 18 Baylor, while the nearby Baha Mar resort follows with two four-team women’s brackets that include No. 2 UConn, No. 7 LSU, No. 17 Mississippi and No. 20 N.C. State. Then come the men’s headliners. The Maui Invitational turns 40 as it opens Monday back in Lahaina. It features second-ranked and two-time reigning national champion UConn, No. 4 Auburn, No. 5 Iowa State and No. 10 North Carolina. The Battle 4 Atlantis opens its 13th men’s tournament Wednesday, topped by No. 3 Gonzaga, No. 16 Indiana and No. 17 Arizona. Michigan State Hall of Famer Tom Izzo is making his fourth trip to Maui, where he debuted as Jud Heathcote’s successor at the 1995 tournament. Izzo's Spartans have twice competed at Atlantis, last in 2021. “They’re important because they give you something in November or December that is exciting,” Izzo said. Any drawbacks? “It’s a 10-hour flight,” he said of Hawaii. Mike Tyson, left, slaps Jake Paul during a weigh-in ahead of their heavyweight bout, Thursday, Nov. 14, 2024, in Irving, Texas. (AP Photo/Julio Cortez) In this image taken with a slow shutter speed, Spain's tennis player Rafael Nadal serves during a training session at the Martin Carpena Sports Hall, in Malaga, southern Spain, on Friday, Nov. 15, 2024. (AP Photo/Manu Fernandez) A fan takes a picture of the moon prior to a qualifying soccer match for the FIFA World Cup 2026 between Uruguay and Colombia in Montevideo, Uruguay, Friday, Nov. 15, 2024. (AP Photo/Santiago Mazzarovich) Rasmus Højgaard of Denmark reacts after missing a shot on the 18th hole in the final round of World Tour Golf Championship in Dubai, United Arab Emirates, Sunday, Nov. 17, 2024. (AP Photo/Altaf Qadri) Taylor Fritz of the United States reacts during the final match of the ATP World Tour Finals against Italy's Jannik Sinner at the Inalpi Arena, in Turin, Italy, Sunday, Nov. 17, 2024. (AP Photo/Antonio Calanni) Dallas Cowboys wide receiver Jalen Tolbert (1) fails to pull in a pass against Atlanta Falcons cornerback Dee Alford (20) during the second half of an NFL football game, Sunday, Nov. 3, 2024, in Atlanta. (AP Photo/ Brynn Anderson) Green Bay Packers quarterback Jordan Love, top right, scores a touchdown during the second half of an NFL football game against the Chicago Bears in Chicago, Sunday, Nov. 17, 2024. (AP Photo/Nam Y. Huh) India's Tilak Varma jumps in the air as he celebrates after scoring a century during the third T20 International cricket match between South Africa and India, at Centurion Park in Centurion, South Africa, Wednesday, Nov. 13, 2024. (AP Photo/Themba Hadebe) Columbus Blue Jackets defenseman Zach Werenski warms up before facing the Seattle Kraken in an NHL hockey game Tuesday, Nov. 12, 2024, in Seattle. (AP Photo/Lindsey Wasson) Kansas State players run onto the field before an NCAA college football game against Arizona State Saturday, Nov. 16, 2024, in Manhattan, Kan. (AP Photo/Charlie Riedel) A fan rapped in an Uruguay flag arrives to the stands for a qualifying soccer match against Colombia for the FIFA World Cup 2026 in Montevideo, Uruguay, Friday, Nov. 15, 2024. (AP Photo/Matilde Campodonico) People practice folding a giant United States flag before an NFL football game between the Buffalo Bills and the Kansas City Chiefs, Sunday, Nov. 17, 2024, in Orchard Park, N.Y. (AP Photo/Julia Demaree Nikhinson) Brazil's Marquinhos attempts to stop the sprinklers that were turned on during a FIFA World Cup 2026 qualifying soccer match against Venezuela at Monumental stadium in Maturin, Venezuela, Thursday, Nov. 14, 2024. (AP Photo/Ariana Cubillos) Georgia's Georges Mikautadze celebrates after scoring his side's first goal during the UEFA Nations League, group B1 soccer match between Georgia and Ukraine at the AdjaraBet Arena in Batumi, Georgia, Saturday, Nov. 16, 2024. (AP Photo/Tamuna Kulumbegashvili) Dallas Stars center Mavrik Bourque, right, attempts to score while Minnesota Wild right wing Ryan Hartman (38) and Wild goaltender Filip Gustavsson (32) keep the puck out of the net during the second period of an NHL hockey game, Saturday, Nov. 16, 2024, in St. Paul, Minn. (AP Photo/Ellen Schmidt) Mike Tyson, left, fights Jake Paul during their heavyweight boxing match, Friday, Nov. 15, 2024, in Arlington, Texas. (AP Photo/Julio Cortez) Italy goalkeeper Guglielmo Vicario misses the third goal during the Nations League soccer match between Italy and France, at the San Siro stadium in Milan, Italy, Sunday, Nov. 17, 2024. (AP Photo/Luca Bruno) Cincinnati Bengals tight end Mike Gesicki (88) celebrates after scoring a touchdown against the Las Vegas Raiders during the second half of an NFL football game in Cincinnati, Sunday, Nov. 3, 2024. (AP Photo/Carolyn Kaster) President-elect Donald Trump attends UFC 309 at Madison Square Garden, Saturday, Nov. 16, 2024, in New York. (AP Photo/Evan Vucci) Fans argue in stands during the UEFA Nations League soccer match between France and Israel at the Stade de France stadium in Saint-Denis, outside Paris, Thursday Nov. 14, 2024. (AP Photo/Thibault Camus) Slovakia's Rebecca Sramkova hits a return against Danielle Collins, of the United States, during a tennis match at the Billie Jean King Cup Finals at the Martin Carpena Sports Hall, Thursday, Nov. 14, 2024, in Malaga, southern Spain. (AP Photo/Manu Fernandez) St. John's guard RJ Luis Jr. (12) falls after driving to the basket during the second half of an NCAA college basketball game against New Mexico, Sunday, Nov. 17, 2024, in New York. (AP Photo/Pamela Smith) England's Anthony Gordon celebrates after scoring his side's second goal during the UEFA Nations League soccer match between England and the Republic of Ireland at Wembley stadium in London, Sunday, Nov. 17, 2024. (AP Photo/Kin Cheung) Katie Taylor, left, lands a right to Amanda Serrano during their undisputed super lightweight title bout, Friday, Nov. 15, 2024, in Arlington, Texas. (AP Photo/Julio Cortez) Las Vegas Raiders wide receiver DJ Turner, right, tackles Miami Dolphins wide receiver Malik Washington, left, on a punt return during the second half of an NFL football game, Sunday, Nov. 17, 2024, in Miami Gardens, Fla. (AP Photo/Lynne Sladky) UConn's Paige Bueckers (5) battles North Carolina's Laila Hull, right, for a loose ball during the second half of an NCAA college basketball game in Greensboro, N.C., Friday, Nov. 15, 2024. (AP Photo/Ben McKeown) Get local news delivered to your inbox!Will Utah State or Boise State forfeit vs. San Jose State in the Mountain West semifinals?
Federal prosecutors seek records from company that deployed AI weapons scanner on NYC subway
NEW YORK, Dec. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Wolfspeed, Inc. (NYSE: WOLF) between August 16, 2023 and November 6, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Wolfspeed securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Wolfspeed class action, go to https://rosenlegal.com/submit-form/?case_id=30954 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: The alleged representations in this action concern Wolfspeed’s Mohawk Valley, New York fabrication facility. The complaint alleges that defendants provided the public with revenue projections that depended on the Mohawk Valley fabrication facility ramping its production to meet and/or exceed demand for its 200mm wafer product. According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while simultaneously misrepresenting and/or concealing material adverse facts concerning the true state of Wolfspeed’s growth potential and, in particular, the operational status and profitability of the Mohawk Valley fabrication facility. First, to meet its publicly stated projections, Wolfspeed would have to cancel or otherwise indefinitely suspend planned future projects such as the facility in Saarland, Germany. Second, Wolfspeed would have to terminate a significant portion of its workforce and shutter its Durham, North Carolina fabrication facility. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Wolfspeed class action, go to https://rosenlegal.com/submit-form/?case_id=30954 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.comLSU outlasts UCF 109-102 in triple-OT affair
The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.Bronx US Rep. Ritchie Torres (D) appeared to all but say Frida y that he would mount a challenge to Gov. Kathy Hochul in the 2026 Democratic primary. Torres, who has been rumored to be considering a run for governor himself , declared in a social media post that running Hochul as the state’s Democratic nominee for governor in 2026 could hand the governorship over to the Republicans. He labeled Hochul the “new Joe Biden,” suggesting that Biden running for a second term (and late withdrawal from the race in favor of Vice President Kamala Harris) is what ultimately caused Democrats to lose the White House to President-elect Donald Trump. While not explicitly saying that he would challenge Hochul in the upcoming primary, Torres made clear that someone needs to. “Let’s avoid repeating history and avoid sleepwalking toward impending disaster and defeat,” Torres wrote. Gov. Kathy Hochul briefs reporters on preparations for a port strike on Sept. 30, 2024. Susan Watts/Office of Governor Kathy Hochul Torres also took aim at Hochul’s basement-level approval ratings, as indicated in recent polls. A September 2024 poll by Siena College found that just 34% of New Yorkers surveyed viewed her in a favorable light, the lowest number for her since she became governor in 2021 following the resignation of then-Gov. Andrew Cuomo. “She may be in denial about the depth of her vulnerabilities as a Democratic nominee,” he said. “A Democratic incumbent who is less popular in New York than Donald Trump is in grave danger of losing to a Republican in 2026–an outcome not seen in 30 years.” Torres has represented the 15th Congressional District in the Bronx since 2021, succeeding Jose Serrano in the seat. Prior to that, Torres served in the City Council between 2014 and 2020, and was the first openly gay Bronx resident ever to serve in the city’s legislature. While championing traditional Democratic values such as higher minimum wages and increased affordability, he has also been an outspoken supporter of Israel following the Oct. 7, 2023 terrorist attacks by Hamas , which bristled some progressives and Democratic socialists. During the 2024 general election, Torres easily defeated his Republican challenger, garnering 76.28% of the vote — and actually running ahead of Harris in the presidential race. Harris won the 15th District with 73.6% of the vote. Jen Goodman, a spokesperson for the Hochul campaign, noted that Hochul’s leadership of New York Democrats helped to flip three Republican-held House seats in the Empire State this past election cycle, despite big Trump gains nationally. “Governor Hochul is proud to have led New York Democrats in a successful election cycle, giving Congressman Torres four new Democratic colleagues in Congress,” Goodman said. “The governor remains focused on delivering results for New Yorkers, from driving down crime to lowering costs for working families.” Democrats have won every gubernatorial election in New York since 2006, when then-Attorney General Eliot Spitzer was elected to the state’s chief executive post. However, in winning her first elected term as governor in 2022, Hochul won by little more than seven points against her Republican challenger, then-US Rep. Lee Zeldin of Long Island. That outcome, combined with New York’s rightward trend to Trump in 2024, may give the GOP hope of returning to the governor’s mansion. Rumors are swirling that US Rep. Mike Lawler, who was re-elected to his Lower Hudson Valley seat this month, might be a key contender for the Republican gubernatorial nomination in 2026. The last Republican to serve as New York governor was George Pataki, who upset Democratic Gov. Mario Cuomo in 1994 and went on to serve three terms.